Vitalhub Corp. (TSE:VHI - Free Report) - Equities research analysts at Raymond James reduced their Q3 2025 EPS estimates for Vitalhub in a research note issued to investors on Sunday, May 11th. Raymond James analyst M. Freeman now anticipates that the company will post earnings per share of $0.05 for the quarter, down from their previous estimate of $0.06. Raymond James has a "Moderate Buy" rating on the stock. The consensus estimate for Vitalhub's current full-year earnings is $0.23 per share. Raymond James also issued estimates for Vitalhub's Q3 2026 earnings at $0.07 EPS and FY2027 earnings at $0.35 EPS.
VHI has been the topic of several other research reports. Canaccord Genuity Group lifted their price target on shares of Vitalhub from C$12.00 to C$12.50 and gave the stock a "buy" rating in a research note on Thursday, January 16th. Scotiabank set a C$14.00 target price on shares of Vitalhub and gave the company an "outperform" rating in a research note on Thursday, January 30th. Finally, TD Securities lifted their target price on shares of Vitalhub from C$13.00 to C$14.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of C$12.08.
Read Our Latest Report on Vitalhub
Vitalhub Trading Down 3.4%
Shares of VHI stock opened at C$10.68 on Tuesday. The firm's 50 day moving average is C$9.93 and its 200 day moving average is C$10.64. The stock has a market capitalization of C$577.71 million, a P/E ratio of 173.71, a P/E/G ratio of 1.18 and a beta of 1.26. Vitalhub has a 12-month low of C$6.45 and a 12-month high of C$12.34.
About Vitalhub
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
